By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Mundipharma AG 

St. Alban-Rheinweg 74

Basel    CH-4006  Switzerland
Phone: 41-61-2051112 Fax: 41-61-2051109



Company News
Spectrum Pharma (SPPI) Divests Rights To ZEVALIN (ibritumomab tiuxetan) In Japan And Select Other Ex-US Countries To Mundipharma AG 11/18/2015 11:19:41 AM
Mundipharma AG Release: Green Whistle Receives Regulatorry And Marketing Approval In The United Kingdom 10/28/2015 3:02:11 PM
Mundipharma AG: New Study Provides Insights Into Potential Treatment Of Severe Pain In Parkinson’s Disease With Prolonged-Release Oxycodone/Naloxone 10/20/2015 10:52:23 AM
Mundipharma AG And Medical Developments International Announce A New Alliance For The Commercialisation Of Penthrox In Europe 9/14/2015 12:44:26 PM
Esteve S.A. (Laboratorios Del Dr. Esteve S.A.) Could Bank $1 Billion From Mundipharma AG, Purdue Pharma L.P. Pain Pact 1/12/2015 6:04:11 AM
Mundipharma AG Receives Positive European Commission Decision On Targin® (Oxycodone/Naloxone) For The Treatment Of Restless Legs Syndrome 1/7/2015 10:38:43 AM
Mundipharma AG Receives Positive CHMP Opinion For Targin® (Oxycodone / Naloxone) For The Treatment Of Restless Legs Syndrome1 10/24/2014 10:56:59 AM
Mundipharma AG Presents Four Posters On “Pain Management In Asia” At The International Association For The Study Of Pain’s 15th World Congress On Pain In Buenos Aires, Argentina 10/6/2014 10:38:43 AM
Skyepharma PLC (SKYEF)’s Partner Mundipharma AG Announces Results Of Pivotal Phase III Study For Flutiform® In Paediatric Asthma 9/8/2014 9:11:21 AM
SkyePharma Inc. (SKYE) Release: Flutiform® Launched In France €3 Million Milestone Receivable From Mundipharma AG 2/10/2014 9:34:03 AM